Jasper Therapeutics- Warrants (24/09/2026) Operating Income

The latest operating income for JSPRW is $-55M as of June 2026. That compares with $-94M in the prior-year period — up 41.3% year over year. Investors often review this figure alongside Jasper Therapeutics- Warrants (24/09/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, JSPRW's operating income moved from $-94M to $-55M — a 41.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jasper Therapeutics- Warrants (24/09/2026)'s operating scale or balance-sheet position.

A operating income figure of $-55M for JSPRW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting JSPRW's operating income ($-55M), review year-over-year change from $-94M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.